000125992 001__ 125992
000125992 005__ 20231006143321.0
000125992 0247_ $$2doi$$a10.1038/s41598-023-33682-2
000125992 0248_ $$2sideral$$a133517
000125992 037__ $$aART-2023-133517
000125992 041__ $$aeng
000125992 100__ $$0(orcid)0000-0003-3392-7200$$aIrún, Pilar
000125992 245__ $$aSerum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study
000125992 260__ $$c2023
000125992 5060_ $$aAccess copy available to the general public$$fUnrestricted
000125992 5203_ $$aCoronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been characterized by an increase of serum pro-inflammatory cytokine levels which seems to be associated with fatal cases. By contrast, the role of pro-resolving lipid mediators (SPMs), involved in the attenuation of inflammatory responses, has been scarcely investigated, so further studies are needed to understand SPMs metabolism in COVID-19 and other infectious diseases. Our aim was to analyse the lipid mediator metabolome, quantifying pro- and anti-inflammatory serum bioactive lipids by LC–MS/MS in 7 non-infected subjects and 24 COVID-19 patients divided into mild, moderate, and severe groups according to the pulmonary involvement, to better understand the disease outcome and the severity of the pulmonary manifestations. Statistical analysis was performed with the R programming language (R Foundation for Statistical Computing, Vienna, Austria). All COVID-19 patients had increased levels of Prostaglandin E2. Severe patients showed a significant increase versus controls, mild- and moderate-affected patients, expressed as median (interquartile range), in resolvin E1 [112.6 (502.7) vs 0.0 (0.0) pg/ml in the other groups], as well as in maresin 2 [14.5 (7.0) vs 8.1 (4.2), 5.5 (4.3), and 3.0 (4.0) pg/ml, respectively]. Moreover, 14-hydroxy docosahexaenoic acid (14-HDHA) levels were also increased in severe vs control and mild-affected patients [24.7 (38.2) vs 2.4 (2.2) and 3.7 (6.4) ng/mL, respectively]. Resolvin D5 was also significantly elevated in both moderate [15.0 (22.4) pg/ml] and severe patients [24.0 (24.1) pg/ml] versus controls [0.0 (0.0) pg/ml]. These results were confirmed by sparse partial least squares discriminant analysis which highlighted the contribution of these mediators to the separation between each of the groups. In conclusion, the potent inflammatory response to SARS-CoV-2 infection involves not only pro- but also anti-inflammatory lipid mediators that can be quantified in easily accessible serum samples, suggesting the need to perform future research on their generation pathways that will help us to discover new therapeutic targets.
000125992 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00$$9info:eu-repo/grantAgreement/ES/DGA/B25-17R$$9info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17R$$9info:eu-repo/grantAgreement/ES/ISCIII/COV20-00308
000125992 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000125992 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000125992 700__ $$aGracia, Rafael
000125992 700__ $$0(orcid)0000-0001-5813-3445$$aPiazuelo, Elena$$uUniversidad de Zaragoza
000125992 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000125992 700__ $$aMorte, Elena$$uUniversidad de Zaragoza
000125992 700__ $$0(orcid)0000-0002-9600-8116$$aPaño, José Ramon$$uUniversidad de Zaragoza
000125992 700__ $$aBoza, Julio
000125992 700__ $$aCarrera-Lasfuentes, Patricia
000125992 700__ $$aHiguera, Gustavo A.
000125992 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Ángel$$uUniversidad de Zaragoza
000125992 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000125992 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000125992 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000125992 773__ $$g13 (2023), 6497 [14 pp.]$$pSci. rep. (Nat. Publ. Group)$$tScientific reports (Nature Publishing Group)$$x2045-2322
000125992 8564_ $$s1995380$$uhttps://zaguan.unizar.es/record/125992/files/texto_completo.pdf$$yVersión publicada
000125992 8564_ $$s2686646$$uhttps://zaguan.unizar.es/record/125992/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000125992 909CO $$ooai:zaguan.unizar.es:125992$$particulos$$pdriver
000125992 951__ $$a2023-10-06-14:13:51
000125992 980__ $$aARTICLE